Nella, A A <br/><br/>
Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.  [electronic resource] 

 -  The Journal of clinical endocrinology and metabolism  Sep 2014 
 - 3055-9 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article; Research Support, N.I.H., Intramural 
<br/><br/><label>ISSN: </label>1945-7197 
<br/><br/><label>Standard No.: </label>10.1210/jc.2013-4340  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adrenocorticotropic Hormone--metabolism<br/>Carcinoma, Neuroendocrine<br/>Clinical Trials, Phase I as Topic<br/>Clinical Trials, Phase II as Topic<br/>Cushing Syndrome--etiology<br/>Humans<br/>Male<br/>Multiple Endocrine Neoplasia Type 2b--complications<br/>Neoplasms, Second Primary--complications<br/>Piperidines--therapeutic use<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Quinazolines--therapeutic use<br/>Thyroid Neoplasms--complications